Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.
Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related...
Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation.The...
Shares of Precigen, Inc. PGEN have skyrocketed 144.4% in August so far, following the company's announcement of the FDA approval for Papzimeos (zopapogene imadenovec-drba) for the treatment of adults...
For Immediate ReleaseChicago, IL – August 14, 2025 – Stocks in this week’s article are Modine Manufacturing Co. MOD, Tutor Perini Corp. TPC, Kiniksa Pharmaceuticals International plc KNSA, Life360...
U.S. stock markets have maintained their northward journey in the first half of August despite tariff and trade-related uncertainties and the Fed’s indecision regarding the timing of the first interest...
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable. The demand for healthcare products and services typically holds up very well regardless...
Mark Ragosa, the CHIEF FINANCIAL OFFICER of $KNSA ($KNSA), sold 1,123 shares of the company on 12-05-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.7%...
Michael R Megna, the CHIEF ACCOUNTING OFFICER of $KNSA ($KNSA), sold 9 shares of the company on 11-29-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.0%...